ASCO GU 2018: Using Grade of Tumor Recurrence After BCG to Guide Further Therapy
San Francisco, CA (UroToday.com) At today’s GU ASCO poster session, Dr. Roger Li from MD Anderson Cancer Center presented findings regarding the use of grade of tumor recurrence after BCG for guiding further therapy. Tumors that recur after BCG therapy are considered to be high risk and patients are often recommended to undergo radical cystectomy.
ASCO GU 2018: Best of Journals: Urothelial Carcinoma – Translational Science
San Francisco, CA (UroToday.com) In this session, Dr. Huddart discussed various articles published in 2017 focusing on translational aspects of urothelial carcinoma. The first topic Dr. Huddart examined was molecular subtypes and phenotypes of urothelial carcinoma. Five expression profiles have been identified in the literature: luminal papillary, luminal infiltrated, luminal, basal squamous, and neuronal. Of which, basal squamous and luminal papillary were most commonly seen.
ASCO GU 2018: Best of Journals: Urothelial Carcinoma
San Francisco, CA (UroToday.com) Dr. Sam Chang, from Vanderbilt University Medical Center presented important articles addressing the study of urothelial carcinoma, from the perspective of a urologist. Dr. Chang began by highlighting a phase II trial evaluating the intravesical use of rAd-INFa/Syn3 (Instiladrin) for patients with high grade (HG) BCG refractory or relapsed non-muscle invasive urothelial carcinoma of the bladder which was published in 2017. rAd-INFa is a replication-deficient adenovirus-based gene transfer vector that encodes the human interferon alpha-2b gene.
ASCO GU 2018: Next Generation Sequencing of Urothelial Bladder Cancer: Memorial Sloan Kettering Cancer Center Experience in 454 Patients
San Francisco, CA (UroToday.com) Genomic characterization of urothelial bladder cancer (UBC) may help to identify alterations associated with tumor stage, novel therapeutic targets and biomarkers to predict outcomes.
ASCO GU 2018: Real-world Survival and Treatment Patterns of Patients with Locally Advanced or Metastatic Urothelial Carcinoma Treated with Second-line Therapy After Platinum-based Chemotherapy
San Francisco, CA (UroToday.com) The median overall survival for patients with locally advanced/metastatic urothelial carcinoma (UC) who fail standard platinum-containing chemotherapy is 5–7 months, and there is no current standard of care for these patients. As immuno-oncology (IO) therapies are being developed for the treatment of UC, a better understanding of the current real-world treatment patterns and effectiveness of treatments is needed.
ASCO GU 2018: The impact of neoadjuvant chemotherapy on conditional survival among patients with muscle-invasive bladder cancer
San Francisco, CA (UroToday.com) Dr. Nikhil Waingankar and colleagues presented their results of neoadjuvant chemotherapy on conditional survival for patients with muscle-invasive bladder cancer (MIBC) at this afternoon’s poster session at GU ASCO. Achieving a pathologic complete response with neoadjuvant chemotherapy for MIBC is associated with a favorable prognosis (55% risk reduction for death ), however patients with pathologic residual disease generally have poor outcomes.
ASCO GU 2018: Distress Prevalence and Associated Risk Factors within the Urothelial Cancer Population
San Francisco, CA (UroToday.com) Dr. Laurel Ralston presented findings regarding distress prevalence and associated risk factors among patients with urothelial cancer. Prevalence of distress has been estimated as high as 40% in some cancer populations, but there is a paucity of literature regarding distress in bladder cancer patients. Distress has been linked with multiple negative clinical outcomes, with the Commission on Cancer now requiring standardized distress screening for cancer program accreditation. The objective of this study was to identify prevalence of distress, associated clinical risk factors and psychosocial referral trends in the urothelial cancer population.